Form 4: Aquestive CMO Sells Shares via 10b5-1 Plan

Aquestive Therapeutics' Chief Medical Officer, Carl N. Kraus, sold 20,272 shares of common stock for a weighted average price of $7.00 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Carl N. Kraus, Chief Medical Officer of Aquestive Therapeutics, Inc. (AQST), reported the sale of 20,272 shares of common stock.
• The transaction occurred on October 15, 2025.
• The shares were sold at prices ranging from $7.00 to $7.02 per share, with a weighted average price of $7.00 per share.
• The sale was executed pursuant to a Rule 10b5-1 Trading Plan previously adopted by Mr. Kraus.
• Following this transaction, Mr. Kraus directly beneficially owns 282,475 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can be perceived negatively, the fact that it was executed under a pre-arranged 10b5-1 plan reduces concerns about its implications for the company's immediate prospects. It's a routine, planned transaction.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than a reaction to new, non-public information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived as a lack of confidence by some investors, though the 10b5-1 plan mitigates this concern.

Risks

• No specific risks were mentioned in this Form 4 filing beyond the general perception associated with insider selling, which is mitigated by the 10b5-1 plan.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction disclosure (Form 4) and does not provide specific insights into broader industry trends or competitive landscape. Such filings are standard for publicly traded companies when insiders buy or sell shares.

Comparison to Industry Standards

• This Form 4 filing is a standard regulatory disclosure for insider transactions, consistent with SEC requirements for reporting changes in beneficial ownership by officers, directors, and 10% owners.
• The use of a Rule 10b5-1 trading plan is a common practice among corporate insiders to sell shares in a pre-arranged manner, mitigating concerns about trading on material non-public information, aligning with best practices for corporate governance.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but its execution under a 10b5-1 plan suggests it is not based on new, adverse information, thus minimizing potential negative impact on shareholder confidence.

Key Dates

Recommendation

The filing details a routine insider stock sale executed under a pre-arranged 10b5-1 trading plan. This type of transaction is generally not indicative of new material information about the company's performance or outlook. Therefore, it does not provide a strong signal to alter an investment position, warranting a 'hold' recommendation.

Keywords

Aquestive Therapeutics, AQST, Carl N. Kraus, Chief Medical Officer, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Equity Transaction